TPA in Stroke: What's All the Fuss?. FERNE Brain Illness and Injury Course.

Slides:



Advertisements
Similar presentations
3/28/2017© 2009, American Heart Association. All rights reserved.
Advertisements

UPDATE ON THROMBOLYTIC THERAPY Markku Kaste Department of Neurology Helsinki University Central Hospital (HUCH) University of Helsinki Markku Kaste Department.
STROKE UPDATE Carlos S. Kase, M.D. Department of Neurology Boston Medical Center Medicine Grand Rounds New England Baptist Hospital March 17, 2011.
Heather M. Prendergast, MD, MPH EMRA/FERNE Case Conference: Legal Issues in the ED Management of Acute Ischemic Stroke Patients.
Accomplishments in Stroke Care
Thrombolysis for stroke in older people.
The NINDS rt-PA Stroke Trial Prior information(Pre-Clinical, Phase I Studies, etc) Thrombolytic canalization of occluded arteries may reduce the degree.
TPA… SMART or not SMART? That is the Question. Sarah Parker, MD.
Hyperacute Stroke Treatment: Inclusion and Exclusion Criteria
Efficacy and Safety of Fondaparinux in Elderly Patients With ST-Segment Elevation Myocardial Infarction: Data From the OASIS 6 Trial Efficacy and Safety.
Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.
Disclosures: Maximo C. Kiok, M.D. Medical Director of Stroke Program Trinity Health System.
Target: Stroke Building on Success A national quality improvement initiative of the American Heart Association/American Stroke Association to improve.
J. Stephen Huff, MD ED Stroke Patient Management: What must we be able to do in order to provide tPA in the ED? (mimics, stroke scales, timing, and CT.
Clinical Use of tPA in Acute Ischemic Stroke Edward P. Sloan, MD, MPH Associate Professor Department of Emergency Medicine University of Illinois College.
Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of.
The third international stroke trial (IST-3) of thrombolysis main results III. Effect of iv thrombolysis with iv rt-PA on death or dependency in the 3035.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
Brain Single-Photon Emission CT With HMPAO and Safety of Thrombolytic Therapy in Acute Ischemic Stroke Proceedings of the Meeting of the SPECT Safe Thrombolysis.
E. Bradshaw Bunney, MD Stroke Care within the 3 Hour IV tPA Window: Why IV tPA, or What Alternatives?
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
Thrombolysis and Beyond: The New Therapeutic Horizons for Acute Ischemic Stroke
TPA in Acute Ischemic Stroke: The NINDS Reanalysis & Meta-analysis Data Sidney Starkman, MD, FACEP.
T-PA in Treatment of Acute Stroke: What We Know From NINDS 2004 vs 2000 Sidney Starkman, MD Departments of Emergency Medicine and Neurology, UCLA UCLA.
Edward P. Sloan, MD, MPH, FACEP Emergency Department Patient Hypertensive Emergencies: Published Guidelines, Articles, & Their Findings.
FERNE/MEMC Session: Treating Ischemic Stroke in the 3 – 4
Edward P. Sloan, MD, MPH FERNE/EMA Session: Treating Ischemic Stroke Patients Using a 3 to 4.5 Hour tPA Window.
SYDNEY MEDICAL SCHOOL What do the IST-3 results mean for the elderly patient with acute stroke? Westmead Hospital Clinical School | George Institute for.
Clinical Use of tPA in Acute Ischemic Stroke. Edward P. Sloan, MD, MPH Associate Professor Department of Emergency Medicine University of Illinois College.
Clinical Use of tPA in Acute Ischemic Stroke Edward P. Sloan, MD, MPH Associate Professor Department of Emergency Medicine University of Illinois College.
Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of.
Evidence based stroke medicine. Evaluating treatments for acute ischaemic stroke -what works and what doesn’t? Professor Peter Sandercock.
Original Article Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke Werner Hacke, M.D., Markku Kaste, M.D., Erich Bluhmki, Ph.D., Miroslav.
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
10 May 2005 CASES - Original article available at CASES (Canadian Alteplase for Stroke Effectiveness Study) The CASES Investigators.
What’s on the horizon? Peter Sandercock ESC Lisbon 23rd May 2012.
Thrombolysis in acute ischaemic stroke – Updated Cochrane Thrombolysis metaanalysis JM Wardlaw, V Murray, PAG Sandercock University of Edinburgh and Karolinska.
Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Evidence in the ED Byron Drumheller, MD Penn Emergency Medicine.
Overview of new acute stroke trials Shawna Cutting, MD, MS Rush University Medical Center June 9, 2015.
Evidence based stroke medicine. Evaluating treatments for acute ischaemic stroke -what works and what doesn’t? Professor Peter Sandercock.
S afe I mplementation of T hrombolysis in S troke Slide presentation adapted from
RMH Comprehensive Stroke Centre Thrombolysis and Stroke Units : The Evidence Professor Stephen Davis Royal Melbourne Hospital Comprehensive Stroke Centre.
Treatment of Ischaemic Stroke The American Heart Association American Stroke Association Guidelines Stroke. 2007;38:
Acute Ischemic Stroke Treatments Patrick J. Ward, PA-S.
Mr X, 79 years old Admitted on 5/5/00 to WGH stroke unit Dense (0/5) right arm and leg paresis Aphasic CT scan excluded a bleed Given trial treatment (IST-3)
Thrombolysis for patients > 80 – a different view Peter Sandercock On behalf of the IST3 collaborative Group UKSF Glasgow 1 st December 2009.
The Use of tPA in Acute Ischemic Stroke Edward P. Sloan, MD, MPH Professor Department of Emergency Medicine University of Illinois College of Medicine.
Can patients be too mild, too severe or too old for thrombolysis? Professor Peter Sandercock University of Edinburgh ESC Hamburg 27 th May 2011 Disclosures.
Stroke : To Lyse or Not to Lyse ? Understand the Literature and Decide : What is best for your practice environment ?
Applying CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage 2) in a Pre- Hospital Wilderness Context Paul B. Jones PGY1.
Risk of bolus thrombolytics Shamir Mehta, MD Director, Coronary Care Unit McMaster University Medical Center Hamilton, Ontario Paul Armstrong, MD Professor.
Richard Shih, MD, FACEP Stroke Patient Management Using IV tPA: When and How Should It Be Utilized in ED Patients?
Thrombolysis for acute ischaemic stroke Clinical
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Clinical Use of tPA in Acute Ischemic Stroke Edward P. Sloan, MD, MPH Associate Professor Department of Emergency Medicine University of Illinois College.
Sanaz Sakiani, MD Endocrinology Fellow Journal Club
Table 1: Table 2: Non Therapeutic Angiograms in Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Does not Adversely Affect Patient.
Thrombectomy in Acute Stroke
Clinical Audit of Head CT in Stroke Alert Cases: Role of Radiology Resident and CT Technologist Awareness in improving Head CT reporting time K Hooda,
Acute Stroke Therapy with IV Thrombolysis Lawrence R. Wechsler, M.D.
Martha Carvour, MD, PhD March 2, 2017
When Not to Intervene in Acute Stroke or
Setareh Omran, MD Vascular Neurology Fellow
Modified Rankin score 0-2
Three Steps to Interpret Clinical Trials
Extended Window Thrombectomy
Update from education committee
Three outcome measures from the NINDS tPA trial
MOST Study Update and Endovascular Discussion
Presentation transcript:

tPA in Stroke: What's All the Fuss?

FERNE Brain Illness and Injury Course

Joseph Lex, MD 4 th Mediterranean Emergency Medicine Congress Sorrento, Italy 17 September th Mediterranean Emergency Medicine Congress Sorrento, Italy 17 September 2007

Joseph Lex, MD Joseph R. Lex Jr. MD, FAAEM Assistant Professor Department of Emergency Medicine Temple University School of Medicine Philadelphia, PA US

Joseph Lex, MD Advisory Board, FERNE Editorial Board, Editorial Board, Medscape Emergency Medicine

Joseph Lex, MD Disclosures None

Objectives Review the results of the NINDS clinical trials Review the results of the NINDS clinical trials Discuss Phase Four clinical data on clinical use of tPA for stroke Discuss Phase Four clinical data on clinical use of tPA for stroke Describe an appropriate informed consent for use of tPA in stroke Describe an appropriate informed consent for use of tPA in stroke

Joseph Lex, MD In the Beginning…

Joseph Lex, MD

NINDS Trial Results tPAPlacebo Number of patients Modified Rankin Scale Modified Rankin Scale 40% (63) 28% (41) Glasgow Outcome Scale Glasgow Outcome Scale 43% (68) 32% (46) NIH Stroke Score NIH Stroke Score 34% (53) 20% (29) Symptomatic ICH in 36 hours 6.4% (10) 0.6% (1) Death by 90 days 17% (27) 21% (30)

Joseph Lex, MD IV Thrombolysis: Up Side Rankin: 12% absolute benefit Rankin: 12% absolute benefit Glasgow: 11% absolute benefit Glasgow: 11% absolute benefit NIHSS: 14% absolute benefit NIHSS: 14% absolute benefit Conclusion: treat 7 – 8 patients with t-PA to have one additional patient with better outcome Conclusion: treat 7 – 8 patients with t-PA to have one additional patient with better outcome

Joseph Lex, MD NINDS Trial Results tPAPlacebo Number of patients Modified Rankin Scale Modified Rankin Scale 40% (63) 28% (41) Glasgow Outcome Scale Glasgow Outcome Scale 43% (68) 32% (46) NIH Stroke Score NIH Stroke Score 34% (53) 20% (29) Symptomatic ICH in 36 hours 6.4% (10) 0.6% (1) Death by 90 days 17% (27) 21% (30)

Joseph Lex, MD IV Thrombolysis : Down Side 6% absolute increase in number of symptomatic intracranial hemorrhages 6% absolute increase in number of symptomatic intracranial hemorrhages Conclusion: treat 16 patients with tPA to have one additional symptomatic intracranial hemorrhage Conclusion: treat 16 patients with tPA to have one additional symptomatic intracranial hemorrhage

Joseph Lex, MD IV Thrombolysis: Summary So if you treat 1000 patients who meet t-PA criteria… …120 will have an absolute benefit, but… …60 will have symptomatic intracranial haemorrhage

Joseph Lex, MD IV Thrombolysis: Summary Two patients will have minimal or no deficit for every one patient with symptomatic intracranial hemorrhage

Joseph Lex, MD NINDS: Design Issues Patients were excluded if… …blood pressure > 185/110 mm Hg …required “aggressive treatment” of blood pressure …anti-coagulated within 48 hours …anti-platelet treatment within 24 hours

Joseph Lex, MD And then… …Jeff Mann and …Jerome Hoffman and …Jeanne Lenzer and …several others looked more closely at the data.

Baseline NIHSS % tPA (n=153) % placebo (n=167) 0 – % (29) 4.2% (7) 6 – % (37) 27.5% (46) 11 – % (26) 21.0% (35) 16 – % (33) 19.8% (33) > % (28) 27.5% (46)

Baseline NIHSS % tPA (n=153) % placebo (n=167) 0 – % (29) 4.2% (7) 6 – % (37) 27.5% (46) 11 – % (26) 21.0% (35) 16 – % (33) 19.8% (33) > % (28) 27.5% (46)

Joseph Lex, MD NINDS Baseline Imbalance Corrected 0 – 90 minutes 91 – 180 minutes 0 – 180 minutes tPA32%39%36% Placebo33%32%32% Wardlaw JM, Lindley RI, Lewis S. Thrombolysis for acute ischemic stroke: still a treatment for the few by the few. West J Med May;176(3): Simple random assignment accounted for 4% of the absolute reduction

Joseph Lex, MD IV Thrombolysis: Summary So if you treat 1000 patients who meet t-PA criteria… …80 will have an absolute benefit, but… …60 will have symptomatic intracranial haemorrhage

Joseph Lex, MD NINDS in Clinical Practice Must consider tPA, but patient selection very difficult Must consider tPA, but patient selection very difficult Must maximize risk/benefit ratio Must maximize risk/benefit ratio Must avoid haemorrhage, if possible Must avoid haemorrhage, if possible Need adequate severity, but not too severe Need adequate severity, but not too severe <2% of stroke patients meet criteria <2% of stroke patients meet criteria

Joseph Lex, MD Phase IV Post-Marketing Studies

Joseph Lex, MD Phase IV tPA Use Many later publications Many later publications Mix of community and academic centers Mix of community and academic centers 37 to 389 patients (312 in NINDS trials) at one to 57 hospitals 37 to 389 patients (312 in NINDS trials) at one to 57 hospitals Treatment given to 1.8% - 22% of eligible patients Treatment given to 1.8% - 22% of eligible patients

Joseph Lex, MD Phase IV t-PA trials Author Patients receiving tPA(%) Mean time to Rx Favorable outcome % ICH % Symptomatic ICH % Protocol deviation NINDS %10.9%6.4% Chiu30(2.9%)2’37”63%10%6.6% Tanne189>2’9%5.8%30% Wang57(6.3%)2’28”44-54%9%5%9% Buchan68(4.4%)95%31%9%16% Albers3892’44”35-43%11.5%3.3%33% Katzan70(1.8%)22%15.7%50% Chapman46(1.8%)2’45”30-48%9%2.2%17% Grotta269(16%)2’17”33%4.5%13% Bravata6317%6%67% Total928(5.8%)2’25”33-95%9.6%5.2%13-67%

Joseph Lex, MD Phase IV vs NINDS Age: 63 – 71 years old NINDS = 68 years Median NIHSS: 10 – 15 NINDS = 14 Median time to treatment: 126 – 165 minutes NINDS = 89 minutes

Joseph Lex, MD Phase IV vs NINDS Good outcome: 30 – 95% NINDS = 31 – 54% Mortality: 5.3 – 25% (Mean: 14%) NINDS = 17% Symptomatic ICH: 3.3 – 15.7% (Mean: 5.2%) NINDS = 6.4%

Joseph Lex, MD Phase IV: Deviations In 1.3 – 67% of patients Treatment beyond 180 min: 0 – 22% Anti-coagulant use: 2.2 – 37% BP not controlled: 3 – 7% Baseline coagulopathy: 1.5 – 10% CT showed large stroke: 2 – 15% CT edema or mass effect: 2 – 10% (NINDS 3-5%)

Joseph Lex, MD Phase IV tPA: Overall Time to treatment near 180 minute window Time to treatment near 180 minute window Many protocol violations Many protocol violations Most common protocol violation: giving tPA >180 minutes after symptom onset Most common protocol violation: giving tPA >180 minutes after symptom onset NINDS population and results can be duplicated NINDS population and results can be duplicated

Joseph Lex, MD Cochrane Database Randomised trials of any thrombolytic agent compared with control in patients with definite ischaemic stroke Randomised trials of any thrombolytic agent compared with control in patients with definite ischaemic stroke 18 trials including 5727 patients 18 trials including 5727 patients Not all trials looked at each outcome Not all trials looked at each outcome Sixteen trials were double-blind Sixteen trials were double-blind Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;(3):CD

Joseph Lex, MD Cochrane Database Lytic administered up to 6 hours after ischaemic stroke significantly reduced proportion of patients who were dead or dependent (modified Rankin 3 to 6) at 3 to 6 month follow-up (OR 0.84, 95% CI 0.75 to 0.95) Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;(3):CD

Joseph Lex, MD Cochrane Database In lytic groups there was significant increase in… …odds of death within first 10 days (OR 1.81, 95% CI 1.46 to 2.24), the main cause of which was fatal intracranial haemorrhage (OR 4.34, 95% CI 3.14 to 5.99) Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;(3):CD

Joseph Lex, MD Cochrane Database In lytic groups there was significant increase in… …symptomatic intracranial haemorrhage (OR 3.37, 95% CI 2.68 to 4.22) …death at end of 3 to 6 month follow-up (OR 1.33, 95% CI 1.15 to 1.53) Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;(3):CD

Joseph Lex, MD Cochrane Database If treated within 3 hours of stroke, lytics appeared more effective in reducing death or dependency (OR 0.66, 95% CI 0.53 to 0.83) with no statistically significant adverse effect on death (OR 1.13, 95% CI 0.86 to 1.48) If treated within 3 hours of stroke, lytics appeared more effective in reducing death or dependency (OR 0.66, 95% CI 0.53 to 0.83) with no statistically significant adverse effect on death (OR 1.13, 95% CI 0.86 to 1.48) Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;(3):CD

Joseph Lex, MD Cochrane Database Conclusion Net benefit despite real hazards Net benefit despite real hazards Heterogeneity and wide CI make results unreliable Heterogeneity and wide CI make results unreliable Additional trial data required Additional trial data required Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2003;(3):CD

Joseph Lex, MD Informed Consent

Joseph Lex, MD What Do We Tell the Patient? “If we do nothing, there is a 40% chance you’ll have good recovery.” “If we give you tPA, there is a 52% chance you will have good recovery after 3 months.” “That means there is a one in eight chance that the drug will help.”

Joseph Lex, MD Explain to Patient / Family “There is no evidence that tPA will make any difference before 3 months, so we won’t know right away if it’s working.” “If we use tPA, there is a one in sixteen chance that you will develop bleeding in your brain.”

Joseph Lex, MD Explain to Patient / Family “Despite this increase in brain bleeding, your risk of being dead at 3 months is about the same with or without tPA.”

Joseph Lex, MD Conclusions

Clinical Considerations Patient selection difficult Patient selection difficult Histories unreliable: must have exact time of onset Histories unreliable: must have exact time of onset Hypodense area on CT: may be old stroke, older than 180 minutes Hypodense area on CT: may be old stroke, older than 180 minutes Old habits: tendency not to intervene Old habits: tendency not to intervene First do no harm First do no harm

Joseph Lex, MD Overall Conclusions Data supports use of IV t-PA when NINDS protocol strictly followed Data supports use of IV t-PA when NINDS protocol strictly followed Outcomes similar to NINDS can be achieved Outcomes similar to NINDS can be achieved Sooner may be better Sooner may be better Narrow therapeutic window Narrow therapeutic window

Joseph Lex, MD Overall Conclusions In practice, relatively few patients receive tPA treatment In practice, relatively few patients receive tPA treatment Document decision-making well on all patients, t-PA or not Document decision-making well on all patients, t-PA or not

Joseph Lex, MD Questions? ferne_memc_2007_braincourse_lex_tpa_091707_finalcd 9/17/2007 5:29 AM